ClinicalTrials.gg
RecruitingNCT07230977Updated Dec 24, 2025

GenSci139 in Patients With Advanced Solid Tumors

A Phase 1 interventional study of GenSci139 in Advanced Solid Tumors, sponsored by Changchun GeneScience Pharmaceutical Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-24.

Sponsored by Changchun GeneScience Pharmaceutical Co., Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Nov 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
280
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a phase I, two-part, multicenter, first-in-human study. The Part 1 study will assess the safety, tolerability, preliminary anti-tumor activities, PK profile, immunogenicity and biomarker of GenSci139 in participants with locally advanced or metastatic solid tumors, as well as identity MTD (if any) and RDE. The Part 2 study is to further evaluate the preliminary anti-tumor activities, safety, PK profile, immunogenicity and biomarker of GenSci139 at RDE dose levels with selected advanced cancers.

02

Conditions studied

  • Advanced Solid Tumors
03

In context

Lead sponsor

Changchun GeneScience Pharmaceutical Co., Ltd. is the lead sponsor of 112 studies on the registry; 48 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Has the ability to understand and the willingness to sign a written document (prior to the initiation dose of GenSci139 and any study procedures).
  • Is willing and able to comply with the scheduled visits, treatment plan, laboratory tests and other specified study procedures.
  • Adult participants (≥18 years of age or acceptable age according to local regulations, whichever is older) at the time of voluntarily signing informed consent.
  • Is able to provide tumor tissues. Fresh specimens or archival tumor tissue samples obtained after last treatment are strongly preferred, and if not available, providing other archival tumor tissue specimens or not may be enrolled after discussion with sponsor.
  • Has at least one by v1.1.
  • Has an eastern cancer collaboration group () status of 0 or 1.
  • (LVEF) ≥50%.
  • Has a of ≥ 3 months.
  • Has adequate hematologic and organ function prior to initiation dose of GenSci139.
  • Women of (WOCBP) must be willing to use adequate while receiving GenSci139, and within 6 months after the last dose of GenSci139 and have a negative serum human chorionic gonadotropin (HCG) test.
  • Nonsterile males must be willing to use adequate contraception for the duration of receiving GenSci139 and within 6 months after the last dose of GenSci139.
  • Has or cytologically confirmed locally advanced or UC, HNSCC, TNBC, NSCLC, BTC, ESCC, GC, CRC, OC, NPC, PDAC etc. and have progressed following standard therapy, or for whom, in the opinion of the investigator, no available and effective standard therapy exists.

Key Exclusion Criteria:

  • Any active within 3 years before initiation dose of GenSci139 except for the cancer under investigation in this study and any locally recurring cancer that has been treated curatively (e.g., resected basal or squamous cell skin cancer, non-muscle invasive bladder cancer (NMIBC), carcinoma in situ of the cervix or breast).
  • Has diagnosed as primary central nervous system (CNS) tumor.
  • Has , unless asymptomatic, neurologically stable and not requiring treatment for at least 4 weeks prior to initiation dose of GenSci139.
  • Has a history of or spinal cord compression.
  • Has stroke or within 6 months prior to initiation dose of GenSci139.
  • Active diseases and inflammatory diseases.
  • Has a history of (non-infectious) interstitial lung disease (ILD) / pneumonitis that required steroids, has current ILD / pneumonitis, or where suspected ILD / pneumonitis cannot be ruled out by imaging at screening.
  • Unstable thrombotic events within 6 months prior to initiation dose of GenSci139.
  • Has severe chronic or active infection
  • Uncontrolled hypertension
  • Has cardiovascular disease
  • Known severe to GenSci139 and/or any of its .
  • Has a history of severe hypersensitivity reactions to other monoclonal antibodies
  • With enough to some therapies specified in protocol.
  • Known infection, active or infection.
  • Has unresolved toxicities from previous anticancer therapy
  • Had received or EGFR monoclonal antibodies, or using TOPO I inhibitor as payload, targeted to HER2 or EGFR ADC, and could not be intolerance of those treatment.
  • Women who are pregnant or lactating or are planning to become pregnant.
  • Uncontrollable pleural effusion, pericardial effusion, or abdominal and pelvic effusion requiring drainage and/or diuretics within 14 days prior to GenSci139 infusion.
  • The other conditions of participation in this clinical trial were not considered appropriate by the investigators.
Terms in these criteria, in plain language(25)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
280 participants (estimated)

Study arms

  • Experimental
    Part1 dose escalation

    dose escalation cohorts of GenSci139 in sequential ascending order

    Drug: GenSci139

  • Experimental
    Part 1 backfill

    backfill study at dose levels proved safety and efficacy during dose escalation

    Drug: GenSci139

  • Experimental
    Part 2 dose expansion

    Dose expansion at RDE dose levels with selected advanced cancers.

    Drug: GenSci139

Interventions

  • DrugGenSci139

    GenSci139 is a bispecific antibody drug conjugate targeting EGFR and HER2.

06

What researchers measure

Primary outcomes

  1. Part 1 and Part2: Incidence of adverse events

    Percentage of patients with adverse events by system organ class and preferred term

    Time frame: From time of informed consent to 30 days post last dose of GenSci139

  2. Dose limiting toxicities (DLTs)

    DLTs are assessed during the DLT observation period and defined as any toxicity in DLT definition in the Clinical Study Protocol

    Time frame: from time of first dose of GenSci139 to end of DLT observation period(approximately 21 days)

  3. Part1: Maximum Tolerated Dose (MTD) and Recommended Doses for Expansion (RDEs)

    To determine the maximum tolerated dose (MTD), if any, and recommend dose of expansion (RDE) for GenSci139

    Time frame: from time of first dose of GenSci139 up to 18 months

  4. Part2: Objective response rate(ORR)

    To evaluate the preliminary anti-tumor activities of GenSci139 as measured by ORR using RECIST criteria v1.1.

    Time frame: approximately 12 months

  5. Part2: disease control rate (DCR)

    To evaluate the preliminary anti-tumor activities of GenSci139 as measured by DCR using RECIST criteria v1.1.

    Time frame: approximately 12 months

  6. Part2: Duration of response (DoR)

    To evaluate the preliminary anti-tumor activities of GenSci139 as measured by DoR using RECIST criteria 1.1.

    Time frame: approximately 24 months

Secondary outcomes

  1. Cmax of GenSci139

    Calculate maximum observed concentration of GenSci139

    Time frame: approximately 24 months

  2. Part1: Cmax of total antibody

    Calculate maximum observed concentration of total antibody

    Time frame: approximately 24 months

  3. Part1: Cmax of free payload

    Calculate maximum observed concentration of free payload

    Time frame: approximately 24 months

  4. Part1: Tmax of GenSci139

    Calculate time of maximum observed concentration of GenSci139

    Time frame: approximately 24 months

  5. Part1: Tmax of total antibody

    Calculate time of maximum observed concentration of total antibody

    Time frame: approximately 24 months

  6. Part1: Tmax of free payload

    Calculate time of maximum observed concentration of free payload

    Time frame: approximately 24 months

  7. Part1: AUC of GenSci139

    Calculate area under the curve of GenSci139

    Time frame: approximately 24 months

  8. Part1: AUC of total antibody

    Calculate area under the curve of total antibody

    Time frame: approximately 24 months

  9. Part1: AUC of free payload

    Calculate area under the curve of free payload

    Time frame: approximately 24 months

  10. Part1: Objective response rate(ORR)

    To evaluate the preliminary anti-tumor activities of GenSci139 as measured by ORR using RECIST criteria v1.1.

    Time frame: approximately 12 months

  11. Part1: disease control rate (DCR)

    To evaluate the preliminary anti-tumor activities of GenSci139 as measured by DCR using RECIST criteria v1.1.

    Time frame: approximately 12 months

  12. Part1: Duration of response (DoR)

    To evaluate the preliminary anti-tumor activities of GenSci139 as measured by DoR using RECIST criteria 1.1.

    Time frame: approximately 24 months

  13. Part1: ADA of GenSci139

    Incidence and titer of anti-drug antibody (ADA)

    Time frame: approximately 24 months

  14. Part1: NAb of GenSci139

    Incidence and titer of neutralizing antibody (NAb)

    Time frame: approximately 24 months

  15. Part2: Cmax of GenSci139

    Calculate maximum observed concentration of GenSci139

    Time frame: approximately 24 months

  16. Part2: Cmax of total antibody

    Calculate maximum observed concentration of total antibody

    Time frame: approximately 24 months

  17. Part2: Cmax of free payload

    Calculate maximum observed concentration of free payload

    Time frame: approximately 24 months

  18. Part2: Tmax of GenSci139

    Calculate time of maximum observed concentration of GenSci139

    Time frame: approximately 24 months

  19. Part2: Tmax of total antibody

    Calculate time of maximum observed concentration of total antibody

    Time frame: approximately 24 months

  20. Part2: Tmax of free payload

    Calculate time of maximum observed concentration of free payload

    Time frame: approximately 24 months

  21. Part2: AUC of GenSci139

    Calculate area under the curve of GenSci139

    Time frame: approximately 24 months

  22. Part2: AUC of total antibody

    Calculate area under the curve of total antibody

    Time frame: approximately 24 months

  23. Part2: AUC of free payload

    Calculate area under the curve of free payload

    Time frame: approximately 24 months

  24. Part2: ADA of GenSci139

    Incidence and titer of anti-drug antibody (ADA)

    Time frame: approximately 24 months

  25. Part2: NAb of GenSci139

    Incidence and titer of neutralizing antibody (NAb)

    Time frame: approximately 24 months

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2025 (actual). Primary completion is estimated for Jul 2028, 31 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 22, 2025
First posted
Nov 17, 2025
StartActual
Nov 19, 2025
Primary completionEst.
Jul 7, 2028
CompletionEst.
Jan 8, 2029
Last update
Dec 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07230977
Responsible party
Sponsor
First posted
Nov 17, 2025
Start date
Nov 19, 2025
Primary completion
Jul 7, 2028 (estimated)
Completion
Jan 8, 2029 (estimated)
Last update
Dec 24, 2025

Study contacts

Jinming Yu, MD
Contact
sdyujinming@126.com
0531-67626971

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion